Healthcare
Live Price
Offline$6.00
+0.00% today
Window Change
-17.92%
Window
May 29, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars · May 29, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PeptiDream Inc. (PPTDF) is a Healthcare stock with a market cap of $150.79B and listed on OTC. The stock last traded around $6.00 and down 17.9% across the available one-year price window (May 29, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of -60.3%, EPS growth of -125.7%, a dividend yield of 0.0%. What stands out right now is revenue -60.3%, EPS -125.7%, free cash flow -169.0% with operating margin -26.9% and ROIC -5.0%. Valuation already assumes a fairly strong business story at price/sales 8.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PPTDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPTDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PPTDF Max Drawdown
-18.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PPTDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$11.7B
+24.7% YoY
FY Net Income
$4.4B
+23.3% YoY
Free Cash Flow
$1.1B
-78.9% YoY
Revenue Growth
-60.3%
EPS Growth
-125.7%
Gross Margin
40.6%
Net Margin
-20.2%
Income statement
JPY
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 18.5B | 46.7B | 26.9B | 9.4B | 11.7B |
| Gross Profit | 7.5B | 34.5B | 18.1B | 7.0B | 9.5B |
| Operating Income | -5.0B | 21.1B | 9.0B | 4.4B | 7.0B |
| EBITDA | -2.9B | 23.8B | 10.9B | 5.0B | 8.5B |
| Net Income | -3.8B | 15.0B | 7.6B | 3.6B | 4.4B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.7B | 48.1B | 5.2B | 11.7B | 7.1B |
| Total Assets | 77.1B | 92.8B | 63.9B | 26.6B | 26.3B |
| Total Liabilities | 25.5B | 36.0B | 31.8B | 1.6B | 5.0B |
| Shareholder Equity | 51.6B | 56.8B | 32.0B | 25.0B | 21.2B |
| Total Debt | 17.1B | 19.6B | 21.0B | 0 | 0 |
| Net Debt | -11.7B | -28.5B | 15.8B | -11.7B | -7.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.7B
-74.0% YoY
Capital Expenditures
586M
+51.7% YoY
Free Cash Flow
1.1B
-78.9% YoY
Key ratios
Gross Margin
40.6%
Operating Margin
-26.9%
Net Margin
-20.2%
ROE
-7.1%
Debt / Equity
0.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.